https://www.pharmaceutical-technology.com/news/bayer-hyrnuo-nsclc-frontline-accelerated-fda-label-expansion-approval/
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion - Pharmaceutical...
Sep 10, 2026 - Thoracic oncologists previously touted the potential of Bayer's Hyrnuo in HER2-mutant NSCLC in both the first- and second-line settings.
for thehyrnuosetnsclcfrontlines